Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Gastroenterology Reports
Published in: Current Gastroenterology Reports 5/2010

01-10-2010

The Hypersensitive Esophagus: Pathophysiology, Evaluation, and Treatment Options

Author: Jose M. Remes-Troche

Published in: Current Gastroenterology Reports | Issue 5/2010

Login to get access

Abstract

Visceral hypersensitivity plays a key role in the pathogenesis of esophageal functional disorders such as functional heartburn and chest pain of presumed esophageal origin (noncardiac chest pain). About 80% of patients with unexplained noncardiac chest pain exhibit lower esophageal sensory thresholds when compared to controls during esophageal sensory testing (ie, esophageal barostat, impedance planimetry). Such information has led to prescription of peripherally and/or centrally acting therapies for the management of these patients. This review summarizes and highlights recent and significant findings regarding the pathophysiology, evaluation, and treatment of the hypersensitive esophagus, a central factor in functional esophageal disorders.
Literature
1.
Katz PO, Codario R, Castell DO: Approach to the patient with unexplained chest pain. Compr Ther 1997, 23:249–253.PubMed
2.
Achem S, DeVault K: Recent developments in chest pain of undetermined origin. Curr Gastroenterol Rep 2000, 2:201–209.CrossRefPubMed
3.
•• Galmiche JP, Clouse RE, Bálint A, et al.: Functional esophageal disorders. In The Functional Gastrointestinal Disorders, edn 3. Edited by Drosssman DA, Corazziari E, Spiller RC, et al. Lawrence KS: Allen Press; 2006:369–418. This chapter provides a comprehensive review addressing all the information regarding functional esophageal disorders, from epidemiologic data to new therapeutic options.
4.
Faybush EM, Fass R: Gastroesophageal reflux disease in noncardiac chest pain. Gastroenterol Clin North Am 2004, 33:41–54.CrossRefPubMed
5.
Van Handel D, Fass R: The pathophysiology of non-cardiac chest pain. J Gastroenterol Hepatol 2005, 20:S6–S13.CrossRefPubMed
6.
Mujica V, Mudipalli R, Rao S: Pathophysiology of chest pain in patients with nutcracker esophagus. Am J Gastroenterol 2001, 96:1371–1377.CrossRefPubMed
7.
Clouse RE, Lustman PJ: Psychiatric illness and contraction abnormalities of the esophagus. N Engl J Med 1983, 309:1337–1342.CrossRefPubMed
8.
Cannon RO 3 rd, Benjamin SB: Chest pain as a consequence of abnormal visceral nociception. Dig Dis Sci 1993, 38:193–196.CrossRefPubMed
9.
Olden KW: The psychological aspects of noncardiac chest pain. Gastroenterol Clin North Am 2004, 33:61–67.CrossRefPubMed
10.
Rao SS, Gregersen H, Hayek B, et al.: Unexplained chest pain: the hypersensitive, hyperreactive, and poorly compliant esophagus. Ann Intern Med 1996, 124:950–958.PubMed
11.
Rao SS, Hayek B, Summers RW: Functional chest pain of esophageal origin: hyperalgesia or motor dysfunction. Am J Gastroenterol 2001, 96:2584–2589.CrossRefPubMed
12.
Sarkar S, Aziz Q, Woolf CJ, et al.: Contribution of central sensitisation to the development of non-cardiac chest pain. Lancet 2000, 356:1154–1159.CrossRefPubMed
13.
Lembo AJ: Visceral hypersensitivity in noncardiac chest pain. Gastroenterol Clin North Am 2004, 33:55–60.CrossRefPubMed
14.
• Nasr I, Attaluri A, Hashmi S, et al.: S Investigation of esophageal sensation and biomechanical properties in functional chest pain. Neurogastroenterol Motil 2010, 22:520–526, e116. This article describes a recent study in a large cohort of patients with functional chest pain (N = 189) that shows 75% of patients had esophageal hypersensitivity during esophageal balloon distension test.
15.
•• Fass R, Gasiorowska A: Refractory GERD: what is it? Curr Gastroenterol Rep 2008, 10:252–257. This article provides an excellent review of the most important findings regarding the mechanisms involved in refractory GERD, and noting the importance of esophageal hypersensitivity in this special group of patients.CrossRefPubMed
16.
Zerbib F, Roman S, Ropert A, et al.: Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006, 101:1956–1963.CrossRefPubMed
17.
Chahal PS, Rao SS: Functional chest pain: nociception and visceral hyperalgesia. J Clin Gastroenterol 2005, 39(Suppl 3):S204–S209.CrossRefPubMed
18.
Patel RS, Rao SSC: Biomechanical and sensory parameters of the human esophagus at four levels. Am J Physiol 1998, 275:G187–G191.PubMed
19.
Rao SSC, Mudipalli RS, Mujica VR, et al.: Effects of gender and age on esophageal biomechanical properties and sensation. Am J Gastroenterol 2003, 98:1688–1695.CrossRefPubMed
20.
Sengupta JN: An overview of esophageal sensory receptors. Am J Med 2000, 108(Suppl 4a):87 S–89 S.
21.
• Fass R: Sensory testing of the esophagus. J Clin Gastroenterol 2004, 38:628–641. This review provides useful information regarding all the sensory tests used to evaluate sensorimotor properties of the esophagus. Although considered as research tools, these tests help address which pathophysiologic mechanism is involved before deciding a symptom-based therapy.CrossRefPubMed
22.
Page AJ, Blackshaw LA: An in vitro study of the properties of vagal afferent fibres innervating the ferret oesophagus and stomach. J Physiol (Lond) 1998, 512:907–916.CrossRef
23.
Beattie DT, Smith JA, Marquess D, et al.: The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol 2004, 143:549–560.CrossRefPubMed
24.
Willert RP, Woolf CJ, Hobson AR, et al.: The development and maintenance of human visceral pain hypersensitivity is dependent on the N-methyl-D-aspartate receptor. Gastroenterology 2004, 126:683–692.CrossRefPubMed
25.
Bertrand C, Nadel JA, Yamawaki I, et al.: Role of kinins in the vascular extravasation evoked by antigen and mediated by tachykinins in guinea pig trachea. J Immunol 1993, 151:4902–4907.PubMed
26.
Page AJ, Blackshaw LA: GABA B receptors inhibit mechanosensitivity of primary afferent endings. J Neurosci 1999, 19:8597–8602.PubMed
27.
Petrocellis DL, Chu CJ, Moriello AS, et al.: Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels. Br J Pharmacol 2004, 143:251–256.CrossRefPubMed
28.
Kollarik M, Ru F: Adenosine activates a subset of nociceptive vagal sensory nerves in esophagus. Gastroenterology 2006, 130(Suppl 2):A-252.
29.
Fass R, Naliboff B, Higa L, et al.: Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology. 1998, 115:1363–1373.CrossRefPubMed
30.
Cervero F, Laird J: From acute to chronic pain: mechanisms and hypothesis. In Progress in Brain Research. Edited by Zimmerman GCM. Elsevier, Amsterdam; 1996:3–16.
31.
Cervero F, Laird J, Garcia-Nicas E: Secondary hyperalgesia and presynaptic inhibition: an update. Eur J Pain 2003, 7:345–351.CrossRefPubMed
32.
Tack J: Is there a unifying role for visceral hypersensitivity and irritable bowel syndrome in non-erosive reflux disease? Digestion 2008, 78(Suppl 1):42–45.CrossRefPubMed
33.
Trimble KC, Pryde A, Heading RC: Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut 1995, 37:7–12CrossRefPubMed
34.
Drewes AM, Arendt-Nielsen L, Funch-Jensen P, Gregersen H: Experimental human pain models in gastro-esophageal reflux disease and unexplained chest pain. World J Gastroenterol 2006, 12:2806–2817.PubMed
35.
Matthews PJ, Aziz Q, Facer P, et al.: Increased capsaicin receptor TRPV1 nerve fibres in the inflamed human oesophagus. Eur J Gastroenterol Hepatol 2004, 16:897–902.CrossRefPubMed
36.
Remes-Troche JM, Chahal P, Mudipalli R, Rao SS: Adenosine modulates oesophageal sensorimotor function in humans. Gut 2009, 58:1049–1055.CrossRefPubMed
37.
Remes-Troche JM, Attaluri A, Hashmi S, et al.: The role of adenosine in esophageal nociception in patients with functional chest pain. Gastroenterology 2009, 136(Suppl 1):A93.
38.
Caviglia R, Ribolsi M, Maggiano N, et al.: Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure. Am J Gastroenterol 2005, 100:543–548.CrossRefPubMed
39.
Vela MF, Craft BM, Sharma N, et al.: Intercellular space distance is increased in refractory heartburn patients with positive symptom index regardless of whether symptoms are caused by acid or nonacid reflux: a study using impedance-pH and electron microscopy. Gastroenterology 2009, 136(Suppl 1):A426.
40.
• Vela MF, Craft BM, Sharma N, et al.: Intercellular space distance is increased in refractory heartburn patients with GERD but not those with functional heartburn (FH): a study using impedance-pH and electron microscopy. Gastroenterology 2009, 136(Suppl 1):A63. This article describes a very important study evaluating the relationship between DIS and esophageal acid exposure in subjects with GERD and functional heartburn. The authors report that DIS may be a helpful tool to discriminate GERD from functional heartburn. Implications for therapy may be that those with increased DIS need improved reflux control, whereas those with functional symptoms may benefit from non-GERD treatments (eg, visceral analgesia).
41.
Aziz Q, Andersson J, Valind S, Thompson D: Identification of human brain loci processing esophageal sensation using positron emission tomography. Gastroenterology 1997, 113:50–97.CrossRefPubMed
42.
Shaker R, Kern M, Arndorfer R, et al.: Cerebral cortical fMRI responses to esophageal acid exposure and distention: a comparative study. Gastroenterology 1996, 130(Suppl 2):A395.
43.
Hobson AR, Khan RW, Sarkar S, et al.: Development of esophageal hypersensitivity following experimental duodenal acidification. Am J Gastroenterol 2004, 99:813–820.CrossRefPubMed
44.
Penagini R, Hebbard G, Horowitz M, et al.: Motor function of the proximal stomach and visceral perception in gastro-oesophageal reflux disease. Gut 1998, 42:251–257.CrossRefPubMed
45.
Sarkar S, Hobson AR, Furlong PL, et al.: Central neural mechanisms mediating human visceral hypersensitivity. Am J Physiol Gastrointest Liver Physiol 2001, 281:G1196–G1202.PubMed
46.
Balaban DH, Yamamoto Y, Liu J, et al.: Sustained esophageal contraction: a marker of esophageal chest pain identified by intraluminal ultrasonography. Gastroenterology 1999, 116:29–37.CrossRefPubMed
47.
Pehlivanov N, Liu J, Mittal R: Sustained esophageal contraction: a motor correlate of heartburn symptom. Am J Physiol Gastrointest Liver Physiol 2001, 281:G743–G751.PubMed
48.
Johnston BT, Lewis SA, Collins JS, et al.: Acid perception in gastro-oesophageal reflux disease is dependent on psychosocial factors. Scand J Gastroenterol 1995, 30:1–5.CrossRefPubMed
49.
Rubenstein JH, Nojkov B, Korsnes S, et al.: Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment Pharmacol Ther 2007, 26:443–452.CrossRefPubMed
50.
Richter JF, Barish CF, Castell DO: Abnormal sensory perception in patients with esophageal chest pain. Gastroenterology 1986, 91:845–852.PubMed
51.
Shapiro M, Green C, Bautista JM, et al.: Functional heartburn patients demonstrate traits of functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity to acid. Am J Gastroenterol 2006, 101:1084–1091.CrossRefPubMed
52.
Remes-Troche JM, Maher J, Mudipalli R, Rao SS: Altered esophageal sensory-motor function in patients with persistent symptoms after Nissen fundoplication. Am J Surg 2007, 193:200–205.CrossRefPubMed
53.
Chen CL, Szczesniak MM, Cook IJ: Evidence for oesophageal visceral hypersensitivity and aberrant symptom referral in patients with globus. Neurogastroenterol Motil 2009, 21:1142–e96.CrossRefPubMed
54.
Remes-Troche JM, Chahal P, Schulze K, Rao SC: Esophageal barostat or impedance planimetry: which is best suited for esophageal sensory testing? Neurogastroenterol Motil 2006, 18:713–714.
55.
Drewes AM, Schipper KP,Dimcevksi C, et al.: Multimodal assessment of pain in the esophagus: a new experimental model. Am J Physiol Gastrointest Liver Physiol 2002, 283:G95–G103.PubMed
56.
Dickman R, Emmons S, Cui H, et al.: The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Aliment Pharmacol Ther 2005, 22:547–555.CrossRefPubMed
57.
Varaia I, Logue E, O’Connor C, et al.: Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J 2000, 140:367–372.CrossRef
58.
Broekaert D, Fischler B, Sifrim D, et al.: Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2006, 23:365–370.CrossRefPubMed
59.
Rodriguez-Stanley S, Zubaidi S, Proskin HM, et al.: Effect of tegaserod on esophageal pain threshold, regurgitation and symptom relief in patients with functional heartburn and mechanical sensitivity. Clin Gastroenterol Hepatol 2006, 4:442–450.CrossRefPubMed
60.
Peghini PL, Katz PO, Castell DO: Imipramine decreases oesophageal pain perception in human male volunteers. Gut 1998, 42:807–813.CrossRefPubMed
61.
Prakash C, Clouse RE: Long term outcome of tricyclic antidepressant treatment of functional chest pain. Dig Dis Sci 1999, 44:81–90.
62.
Clouse RE, Lustman PJ, Eckert TC, et al.: Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology 1987, 92:1027–1036.PubMed
63.
Rao SS, Mudipalli RS, Remes-Troche JM, et al.: Theophylline improves esophageal chest pain—a randomized, placebo-controlled study. Am J Gastroenterol 2007, 102:930–938.CrossRefPubMed
64.
Jones H, Cooper P, Miller V, et al.: Treatment of non-cardiac chest pain: a controlled trial of hypnotherapy. Gut 2006, 55:1403–1408.CrossRefPubMed
65.
Rao SS, Mudipalli RS, Mujica V, et al.: An open-label trial of theophylline for functional chest pain. Dig Dis Sci 2002, 12:2763–2768.CrossRef
66.
Cannon RO, Quyyumi AA, Mincemoyer R, et al.: Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 1994, 330:1411–1417.CrossRefPubMed
Metadata
Title
The Hypersensitive Esophagus: Pathophysiology, Evaluation, and Treatment Options
Author
Jose M. Remes-Troche
Publication date
01-10-2010
Publisher
Current Science Inc.
Published in
Current Gastroenterology Reports / Issue 5/2010
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-010-0122-3

Other articles of this Issue 5/2010

Current Gastroenterology Reports 5/2010 Go to the issue

ReviewPaper

Emerging Pharmacologic Therapies for Irritable Bowel Syndrome

Clinical Trial Report

Clinical Trial Report—The Final Frontier: Small Intestine

ReviewPaper

Colon Ischemia: Recent Insights and Advances

ReviewPaper

Mast Cells

ReviewPaper

Sampling of the Intestinal Microbiota by Epithelial M Cells

ReviewPaper

Intestinal Goblet Cells and Mucins in Health and Disease: Recent Insights and Progress
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits